Skip to main content
Erschienen in: Acta Neuropathologica 6/2012

01.12.2012 | Original Paper

APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38

verfasst von: Maria Luisa Moro, Giorgio Giaccone, Raffaella Lombardi, Antonio Indaco, Andrea Uggetti, Michela Morbin, Stefania Saccucci, Giuseppe Di Fede, Marcella Catania, Dominic M. Walsh, Andrea Demarchi, Annemieke Rozemuller, Nenad Bogdanovic, Orso Bugiani, Bernardino Ghetti, Fabrizio Tagliavini

Erschienen in: Acta Neuropathologica | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Aβ is the main component of amyloid deposits in Alzheimer disease (AD) and its aggregation into oligomers, protofibrils and fibrils is considered a seminal event in the pathogenesis of AD. Aβ with C-terminus at residue 42 is the most abundant species in parenchymal deposits, whereas Aβ with C-terminus at residue 40 predominates in the amyloid of the walls of large vessels. Aβ peptides with other C-termini have not yet been thoroughly investigated. We analysed Aβ38 in the brains of patients with Aβ deposition linked to sporadic and familial AD, hereditary cerebral haemorrhage with amyloidosis, or Down syndrome. Immunohistochemistry, confocal microscopy, immunoelectron microscopy, immunoprecipitation and the electrophoresis separation of low molecular weight aggregates revealed that Aβ38 accumulates consistently in the brains of patients carrying APP mutations in the Aβ coding region, but was not detected in the patients with APP mutations outside the Aβ domain, in the patients with presenilin mutations or in subjects with Down syndrome. In the patients with sporadic AD, Aβ38 was absent in the senile plaques, but it was detected only in the vessel walls of a small subset of patients with severe cerebral amyloid angiopathy. Our results suggest that APP mutations in the Aβ coding region favour Aβ38 accumulation in the brain and that the molecular mechanisms of Aβ deposition in these patients may be different from those active in patients with familial AD associated with other genetic defects and sporadic AD.
Literatur
1.
Zurück zum Zitat Alafuzoff I, Pikkarainen M, Arzberger T et al (2008) Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 115:533–546PubMedCrossRef Alafuzoff I, Pikkarainen M, Arzberger T et al (2008) Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 115:533–546PubMedCrossRef
2.
Zurück zum Zitat Basun H, Bogdanovic N, Ingelsson M et al (2008) Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 65:499–505PubMedCrossRef Basun H, Bogdanovic N, Ingelsson M et al (2008) Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 65:499–505PubMedCrossRef
3.
Zurück zum Zitat Bentahir M, Nyabi O, Verhamme J et al (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96:732–742PubMedCrossRef Bentahir M, Nyabi O, Verhamme J et al (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96:732–742PubMedCrossRef
4.
Zurück zum Zitat Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19:R4–R11PubMedCrossRef Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19:R4–R11PubMedCrossRef
5.
Zurück zum Zitat Bruni AC, Bernardi L, Colao R et al (2010) Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology 74:798–806PubMedCrossRef Bruni AC, Bernardi L, Colao R et al (2010) Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology 74:798–806PubMedCrossRef
6.
Zurück zum Zitat Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98–106PubMedCrossRef Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98–106PubMedCrossRef
7.
Zurück zum Zitat Bugiani O, Giaccone G, Rossi G et al (2010) Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 67:987–995PubMedCrossRef Bugiani O, Giaccone G, Rossi G et al (2010) Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 67:987–995PubMedCrossRef
8.
Zurück zum Zitat Chávez-Gutiérrez L, Bammens L, Benilova I et al (2012) The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261–2274PubMedCrossRef Chávez-Gutiérrez L, Bammens L, Benilova I et al (2012) The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261–2274PubMedCrossRef
9.
Zurück zum Zitat Cupidi C, Capobianco R, Goffredo D et al (2010) Neocortical variation of Aβ load in fully expressed, pure Alzheimer disease. J Alzheimer Dis 19:57–68 Cupidi C, Capobianco R, Goffredo D et al (2010) Neocortical variation of Aβ load in fully expressed, pure Alzheimer disease. J Alzheimer Dis 19:57–68
10.
Zurück zum Zitat Czirr E, Cottrell BA, Leuchtenberger S et al (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem 283:17049–17054PubMedCrossRef Czirr E, Cottrell BA, Leuchtenberger S et al (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem 283:17049–17054PubMedCrossRef
11.
Zurück zum Zitat Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046–32053PubMedCrossRef Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046–32053PubMedCrossRef
12.
Zurück zum Zitat Di Fede G, Catania M, Morbin M et al (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323:1473–1477PubMedCrossRef Di Fede G, Catania M, Morbin M et al (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323:1473–1477PubMedCrossRef
13.
Zurück zum Zitat Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–11127PubMedCrossRef Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–11127PubMedCrossRef
14.
Zurück zum Zitat Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:5–38PubMedCrossRef Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:5–38PubMedCrossRef
15.
Zurück zum Zitat Gallo M, Marcello N, Curcio SA et al (2011) A novel pathogenic PSEN1 mutation in a family with Alzheimer’s disease: phenotypical and neuropathological features. J Alzheimers Dis 25:425–431PubMed Gallo M, Marcello N, Curcio SA et al (2011) A novel pathogenic PSEN1 mutation in a family with Alzheimer’s disease: phenotypical and neuropathological features. J Alzheimers Dis 25:425–431PubMed
16.
Zurück zum Zitat Giaccone G, Arzberger T, Alafuzoff I et al (2011) BrainNet Europe consortium. New lexicon and criteria for the diagnosis of Alzheimer’s disease. Lancet Neurol. 10:298–299PubMedCrossRef Giaccone G, Arzberger T, Alafuzoff I et al (2011) BrainNet Europe consortium. New lexicon and criteria for the diagnosis of Alzheimer’s disease. Lancet Neurol. 10:298–299PubMedCrossRef
17.
Zurück zum Zitat Giaccone G, Morbin M, Moda F et al (2010) Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol 120:803–812PubMedCrossRef Giaccone G, Morbin M, Moda F et al (2010) Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol 120:803–812PubMedCrossRef
18.
Zurück zum Zitat Giaccone G, Tagliavini F, Linoli G et al (1989) Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 97:232–238PubMedCrossRef Giaccone G, Tagliavini F, Linoli G et al (1989) Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 97:232–238PubMedCrossRef
19.
Zurück zum Zitat Grundke-Iqbal I, Iqbal K, Tung YC et al (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci 83:4913–4917PubMedCrossRef Grundke-Iqbal I, Iqbal K, Tung YC et al (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci 83:4913–4917PubMedCrossRef
20.
Zurück zum Zitat Hellström-Lindah E, Viitanen M, Marutle A (2009) Comparison of Abeta levels in the brain of familial and sporadic Alzheimer’s disease. Neurochem Int 55:243–252CrossRef Hellström-Lindah E, Viitanen M, Marutle A (2009) Comparison of Abeta levels in the brain of familial and sporadic Alzheimer’s disease. Neurochem Int 55:243–252CrossRef
21.
Zurück zum Zitat Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32:4693–4697PubMedCrossRef Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32:4693–4697PubMedCrossRef
22.
Zurück zum Zitat Kukar TL, Ladd TB, Robertson P et al (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region. J Biol Chem 286:39804–39812PubMedCrossRef Kukar TL, Ladd TB, Robertson P et al (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region. J Biol Chem 286:39804–39812PubMedCrossRef
23.
Zurück zum Zitat Kumar-Singh S, Theuns J, Van Broeck B et al (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27:686–695PubMedCrossRef Kumar-Singh S, Theuns J, Van Broeck B et al (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27:686–695PubMedCrossRef
24.
Zurück zum Zitat Levy E, Carman MD, Fernandez-Madrid IJ et al (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124–1126PubMedCrossRef Levy E, Carman MD, Fernandez-Madrid IJ et al (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124–1126PubMedCrossRef
25.
Zurück zum Zitat Lue LF, Kuo YM, Roher AE et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862PubMedCrossRef Lue LF, Kuo YM, Roher AE et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862PubMedCrossRef
26.
Zurück zum Zitat Maler JM, Klafki HW, Paul S et al (2007) Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 7:3815–3820PubMedCrossRef Maler JM, Klafki HW, Paul S et al (2007) Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 7:3815–3820PubMedCrossRef
27.
Zurück zum Zitat Marcon G, Giaccone G, Cupidi C et al (2004) Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 63:199–209PubMed Marcon G, Giaccone G, Cupidi C et al (2004) Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 63:199–209PubMed
28.
Zurück zum Zitat McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM (2012) The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer’s disease brain. Brain Res 1450:138–147PubMedCrossRef McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM (2012) The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer’s disease brain. Brain Res 1450:138–147PubMedCrossRef
29.
Zurück zum Zitat Mc Donald JM, Savva GM, Brayne C et al (2010) Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133:1328–1341 Mc Donald JM, Savva GM, Brayne C et al (2010) Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133:1328–1341
30.
Zurück zum Zitat Munter LM, Botev A, Richter L et al (2010) Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J Biol Chem 285:21636–21643PubMedCrossRef Munter LM, Botev A, Richter L et al (2010) Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J Biol Chem 285:21636–21643PubMedCrossRef
31.
Zurück zum Zitat Munter LM, Voigt P, Harmeier A et al (2007) GxxxG motifs within the amyloid precursorprotein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 26:1702–1712PubMedCrossRef Munter LM, Voigt P, Harmeier A et al (2007) GxxxG motifs within the amyloid precursorprotein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 26:1702–1712PubMedCrossRef
32.
Zurück zum Zitat Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254:97–99PubMedCrossRef Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254:97–99PubMedCrossRef
33.
Zurück zum Zitat Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B (2000) Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch Neurol 57:885–887PubMedCrossRef Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B (2000) Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch Neurol 57:885–887PubMedCrossRef
34.
Zurück zum Zitat Obici L, Demarchi A, de Rosa G et al (2005) A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 58:639–644PubMedCrossRef Obici L, Demarchi A, de Rosa G et al (2005) A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 58:639–644PubMedCrossRef
35.
36.
Zurück zum Zitat Piscopo P, Marcon G, Piras MR et al (2008) A novel PSEN2 mutation associated with a peculiar phenotype. Neurology 70:1549–1554PubMedCrossRef Piscopo P, Marcon G, Piras MR et al (2008) A novel PSEN2 mutation associated with a peculiar phenotype. Neurology 70:1549–1554PubMedCrossRef
37.
Zurück zum Zitat Rossi G, Giaccone G, Maletta R et al (2004) A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 63:910–912PubMedCrossRef Rossi G, Giaccone G, Maletta R et al (2004) A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 63:910–912PubMedCrossRef
38.
Zurück zum Zitat Rovelet-Lecrux A, Hannequin D, Raux G et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24–26PubMedCrossRef Rovelet-Lecrux A, Hannequin D, Raux G et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24–26PubMedCrossRef
39.
Zurück zum Zitat Saito T, Suemoto T, Brouwers N et al (2011) Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 14:1023–1032PubMedCrossRef Saito T, Suemoto T, Brouwers N et al (2011) Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 14:1023–1032PubMedCrossRef
40.
Zurück zum Zitat Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed
41.
Zurück zum Zitat Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061PubMedCrossRef Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061PubMedCrossRef
42.
Zurück zum Zitat Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842PubMedCrossRef Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842PubMedCrossRef
43.
Zurück zum Zitat Shepherd C, McCann H, Halliday GM (2009) Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol 118:37–52PubMedCrossRef Shepherd C, McCann H, Halliday GM (2009) Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol 118:37–52PubMedCrossRef
44.
Zurück zum Zitat Shimojo M, Sahara N, Mizoroki T et al (2008) Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta. J Biol Chem 283:16488–16496PubMedCrossRef Shimojo M, Sahara N, Mizoroki T et al (2008) Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta. J Biol Chem 283:16488–16496PubMedCrossRef
45.
Zurück zum Zitat Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1–40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452–460PubMed Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1–40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452–460PubMed
46.
Zurück zum Zitat Takami M, Nagashima Y, Sano Y et al (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042–13052PubMedCrossRef Takami M, Nagashima Y, Sano Y et al (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042–13052PubMedCrossRef
47.
Zurück zum Zitat Takao M, Ghetti B, Murrell JR et al (2001) Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol 60:1137–1152PubMed Takao M, Ghetti B, Murrell JR et al (2001) Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol 60:1137–1152PubMed
48.
Zurück zum Zitat Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRef Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRef
49.
Zurück zum Zitat Tomidokoro Y, Rostagno A, Neubert TA et al (2010) Iowa variant of familial Alzheimer’s disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 176:1841–1854PubMedCrossRef Tomidokoro Y, Rostagno A, Neubert TA et al (2010) Iowa variant of familial Alzheimer’s disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 176:1841–1854PubMedCrossRef
50.
Zurück zum Zitat Van Vickle GD, Esh CL, Kokjohn TA et al (2008) Presenilin-1 280Glu→Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer’s disease. Mol Med 14:184–194PubMed Van Vickle GD, Esh CL, Kokjohn TA et al (2008) Presenilin-1 280Glu→Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer’s disease. Mol Med 14:184–194PubMed
51.
Zurück zum Zitat Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539PubMedCrossRef Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539PubMedCrossRef
52.
Zurück zum Zitat Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272:22364–22372PubMedCrossRef Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272:22364–22372PubMedCrossRef
53.
Zurück zum Zitat Weggen S, Eriksen JL, Das P et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216PubMedCrossRef Weggen S, Eriksen JL, Das P et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216PubMedCrossRef
54.
Zurück zum Zitat Welander H, Frånberg J, Graff C et al (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110:697–706PubMedCrossRef Welander H, Frånberg J, Graff C et al (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110:697–706PubMedCrossRef
55.
Zurück zum Zitat Welge V, Fiege O, Lewczuk P et al (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 116:203–212PubMedCrossRef Welge V, Fiege O, Lewczuk P et al (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 116:203–212PubMedCrossRef
Metadaten
Titel
APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38
verfasst von
Maria Luisa Moro
Giorgio Giaccone
Raffaella Lombardi
Antonio Indaco
Andrea Uggetti
Michela Morbin
Stefania Saccucci
Giuseppe Di Fede
Marcella Catania
Dominic M. Walsh
Andrea Demarchi
Annemieke Rozemuller
Nenad Bogdanovic
Orso Bugiani
Bernardino Ghetti
Fabrizio Tagliavini
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 6/2012
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-012-1061-x

Weitere Artikel der Ausgabe 6/2012

Acta Neuropathologica 6/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.